U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23ClN2O2
Molecular Weight 382.883
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LORATADINE

SMILES

CCOC(=O)N1CCC(CC1)=C2C3=CC=C(Cl)C=C3CCC4=C2N=CC=C4

InChI

InChIKey=JCCNYMKQOSZNPW-UHFFFAOYSA-N
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

HIDE SMILES / InChI

Molecular Formula C22H23ClN2O2
Molecular Weight 382.883
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.

CNS Activity

Curator's Comment: The second generation antihistamines were less soluble in lipid and thus less readily penetrated the blood-brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CLARITIN

Approved Use

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •itchy, watery eyes •sneezing •itching of the nose or throat

Launch Date

1993
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.8 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
27.1 ng/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 ng/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
34.4 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
96 ng × h/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
56.9 ng × h/mL
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14.4 h
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
27 h
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
84.5%
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DESLORATADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M+F
Sources:
Other AEs: Somnolence, Headache...
Other AEs:
Somnolence (10%)
Headache (9%)
Fatigue (5%)
Dry mouth (4%)
Sources:
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Other AEs: Fatigue, Fever...
Other AEs:
Fatigue (2%)
Fever (7%)
Headache (5%)
Influenza-like symptoms (2%)
Constipation (2%)
Diarrhea (3%)
Dyspepsia (2%)
Loose stools (2%)
Stomatitis (2%)
Tooth disorder (2%)
Vomiting (5%)
Earache (2%)
Drowsiness (7%)
Infection viral (2%)
Allergic rhinitis (2%)
Coughing (3%)
Epistaxis (3%)
Pharyngitis (3%)
Rash (2%)
Sources:
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 35.3
Health Status: unhealthy
Age Group: 35.3
Sex: M+F
Sources:
Other AEs: Headache...
Other AEs:
Headache (4.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Somnolence 10%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M+F
Sources:
Dry mouth 4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M+F
Sources:
Fatigue 5%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M+F
Sources:
Headache 9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 29
Health Status: unhealthy
Age Group: 29
Sex: M+F
Sources:
Allergic rhinitis 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Constipation 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Dyspepsia 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Earache 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Fatigue 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Infection viral 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Influenza-like symptoms 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Loose stools 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Rash 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Stomatitis 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Tooth disorder 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Coughing 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Diarrhea 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Epistaxis 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Pharyngitis 3%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Headache 5%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Vomiting 5%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Drowsiness 7%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Fever 7%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
unhealthy, 3.6
Headache 4.2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 35.3
Health Status: unhealthy
Age Group: 35.3
Sex: M+F
Sources:
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Coadministration with either ketoconazole, erythromycin (both CYP3A4 inhibitors) increased AUC of drug by 307%, 40%, respectively; coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103%
Page: 1.0
minor
minor
minor
minor
minor
minor
minor
minor
yes (co-administration study)
Comment: coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103%
Page: 1.0
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.
1999 Dec 15
Central nervous system effects of H1-receptor antagonists in the elderly.
1999 Feb
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.
1999 Jan
Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups.
1999 Jun
Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years' duration.
1999 Sep
Antiallergic effects of H1-receptor antagonists.
2000
Mechanism responsible for epileptogenic activity by first-generation H1-antagonists in rats.
2000 Dec 22
Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.
2000 Jan
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction.
2001
Desloratadine in the treatment of chronic idiopathic urticaria.
2001
Desloratadine activity in concurrent seasonal allergic rhinitis and asthma.
2001
Safety of antihistamines in children.
2001
Evaluation of a four-channel multiplexed electrospray triple quadrupole mass spectrometer for the simultaneous validation of LC/MS/MS methods in four different preclinical matrixes.
2001 Apr 15
Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma.
2001 Apr 20
Newer antihistamines.
2001 Apr 30
[A new antihistamine. Inhibiting inflammation in rhinorrhea and nasal congestion].
2001 Apr 5
Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein.
2001 Aug
Applications of new liquid chromatography-tandem mass spectrometry technologies for drug development support.
2001 Aug 10
Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system.
2001 Dec
Antihistamines and serum adhesion molecule levels.
2001 Jun
High-dose loratadine exposure in a six-year-old child.
2001 Jun
Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
2001 Mar
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
2001 Mar
Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine.
2001 May
Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus.
2001 May 11
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis.
2001 Nov
Effect of specific immunotherapy versus loratadine on serum adhesion molecules.
2001 Oct
Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin.
2001 Oct
Controlled clinical study of the efficacy of loratadine in Nigerian patients with allergic rhinitis.
2001 Sep
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.
2002
Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests.
2002 Apr
A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis.
2002 Jan
The effect of loratadine in exercise-induced asthma.
2002 Jan
Relationship between direct-to-consumer advertising and physician diagnosing and prescribing.
2002 Jan 1
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit.
2002 Jun
Med-psych drug-drug interactions update.
2002 Mar-Apr
Ventricular tachycardia following ingestion of a commonly used antihistamine.
2002 May 6
Patents

Sample Use Guides

Adults and children 6 years and over: 1 tablet daily; not more than 1 tablet in 24 hours
Route of Administration: Oral
In Vitro Use Guide
dose-dependent inhibition of histamine release was observed at loratadine dose above 7 UM. In the rat basophilic leukemia cells (RBL-2H3) experimental system, inhibition by loratadine increased when the concentration of extracellular Ca2+ was reduced from 1.8 to 0.45 mM. Loratadine also inhibited the Mn2+ influx into these cells, thus reflecting the Ca2+ influx.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:00:54 GMT 2025
Edited
by admin
on Mon Mar 31 18:00:54 GMT 2025
Record UNII
7AJO3BO7QN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLARITIN-D COMPONENT LORATADINE
Preferred Name English
LORATADINE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
SCH-29851
Code English
Loratadine [WHO-DD]
Common Name English
1-PIPERIDINECARBOXYLIC ACID, 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YLIDENE)-, ETHYL ESTER
Common Name English
LORATADINE [MART.]
Common Name English
LORATADINE [USP MONOGRAPH]
Common Name English
LORATADINE [EP MONOGRAPH]
Common Name English
LORATADINE [HSDB]
Common Name English
LORATADINE [MI]
Common Name English
BAY76-2211
Code English
LORATADINE [USP-RS]
Common Name English
SCH 29851
Code English
LORATADINE [USAN]
Common Name English
ALAVERT
Brand Name English
loratadine [INN]
Common Name English
NSC-758628
Code English
LORATADINE [ORANGE BOOK]
Common Name English
LORATADINE [VANDF]
Common Name English
LORATADINE [JAN]
Common Name English
CLARITIN
Brand Name English
LORATADINE [EP IMPURITY]
Common Name English
Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate
Systematic Name English
Classification Tree Code System Code
WHO-ATC R06AX13
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
NCI_THESAURUS C29578
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
WHO-VATC QR06AX13
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
LIVERTOX NBK548831
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID2023224
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
IUPHAR
7216
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
NSC
758628
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
SMS_ID
100000092179
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
INN
5864
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
CAS
79794-75-5
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
RS_ITEM_NUM
1370270
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
PUBCHEM
3957
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
MERCK INDEX
m6905
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY Merck Index
DRUG CENTRAL
1605
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
MESH
D017336
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
LACTMED
Loratadine
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
FDA UNII
7AJO3BO7QN
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
EVMPD
SUB08581MIG
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
HSDB
3578
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
USAN
W-119
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
RXCUI
28889
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY RxNorm
ChEMBL
CHEMBL998
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
DAILYMED
7AJO3BO7QN
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
DRUG BANK
DB00455
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
WIKIPEDIA
LORATADINE
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
NCI_THESAURUS
C29162
Created by admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
PRIMARY
Related Record Type Details
BINDER->LIGAND
METABOLIC ENZYME -> INHIBITOR
IC50
TARGET -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
PARENT->INNOVATOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
METABOLITE ACTIVE -> PARENT
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC